Background: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications. In this context, the positron emitter scandium-44 is an attractive alternative for PET imaging. We report the synthesis of [ 44 Sc]Sc-PSMA-617 as radiopharmaceutical with generator produced scandium-44, its in vitro characterization and clinical translation as part of a first in-human study. Methods: Scandium-44 was obtained from a 44 Ti/ 44 Sc radionuclide generator. PSMA-617 was labeled with 142.4±12.7 MBq of scandium-44 in analogy to [ 68 Ga]Ga-PSMA-617 and evaluated in vitro and in cell studies using PSMA+ LNCaP cells. A first-in-human investigation was subsequently carried out in a cohort of 4 patients (mean age 70±1.8 a) registered for [ 177 Lu]Lu-PSMA-617 therapy. 50.5±9.3 MBq (40 µg, 38.4 nmol) [ 44 Sc]Sc-PSMA-617 were applied via intravenous injection (i.v.), respectively. A Siemens Biograph 2 PET/CT system was used to acquire initial dynamic PET data (30 min) of abdomen in list mode followed by static PET/CT data (skull to mid-thigh) at 45 min, 2 and 18 h post-injection (p.i.). For quantitative analysis, dynamic images were reconstructed as 6 data sets of 300 s each. The noise ratio was measured in liver, lung and an additional region outside the body. SUV values in different organs and lesions were measured and compared to [ 68 Ga]Ga-PSMA-11 data of the same patients. Residence times and organ absorbed doses were calculated using OLINDA/EXM software. Results: Quantitative radiochemical yields of ≥98 % were achieved using 18 nmol of PSMA-617 after 20 min at 95 °C with apparent molar activity of 6.69±0.78 MBq/nmol. Following purification, >99 % radiochemical purity was obtained. [ 44 Sc]Sc-PSMA-617 showed high stability (>95 %) in serum for 24 h. The binding affinity and internalization fraction were determined in PSMA+ LNCaP cells (IC50 = 4.72±0.7 nM and internalization fraction: 15.78±2.14 % IA/10 6 LNCaP cells) and compared to [ 68 Ga]Ga-PSMA-11 (12.0±2.8 nM and 9.47±2.56 % IA/10 6 LNCaP cells). Physiological tracer uptake was observed in kidneys, liver, spleen, small intestine, urinary bladder, and salivary glands and pathological uptake in both soft and skeletal metastases. SUV values were significantly lower in the kidneys (14.0) compared to [ 68 Ga]Ga-PSMA-11 OET (30.5). All other measured SUV values did not show a statistically significant difference. Tumor to liver ratios were found to lie between 1.9 and 8.3 for [ 68 Ga]Ga-PSMA-11 and between 2.5 and 8.8 for [ 44 Sc]Sc-PSMA-617 after 120 min. For [ 44 Sc]Sc-PSMA-617 the ratios were higher and no statistically significant differences were observed. Total and % activity were highest in liver followed by kidneys, spleen, small intestine and salivary glands. Rapid wash out was seen in liver and spleen and gradually over time in kidneys. Kidneys received the highest radiation absorbed dose of 0. 354 (0.180-0.488 
Introduction
Prostate specific membrane antigen (PSMA) is expressed in prostate tissue and highly upregulated in prostate cancer (1, 2) . As PSMA is a transmembrane molecule, its extracellular N-terminal part containing the catalytic domain is suitable for selective tumor targeting (3) . A number of different radiopharmaceuticals binding to PSMA have been developed and correlated to prostate specific antigen (PSA) levels. Remarkably, radiolabeled low-molecular weight compounds presented as very promising prostate cancer imaging agents (4-7). Consequently, low-molecular-weight urea-based peptidomimetic inhibitors with high affinity to the catalytic domain of PSMA were developed (5, 8) of which the DOTA derivative PSMA-617 labeled with lutetium-177 (therapeutic radionuclide) or gallium-68 (diagnostic radionuclide) turned out to be a highly powerful theranostic tool for prostate cancer ( Figure 1 ).
First experiences showed that [ 177 Lu]Lu-PSMA-617 is safe and effective in treatment of metastasized castration-resistant prostate cancer (mCRPC) and pre-therapeutic dosimetry may support to improve therapy planning as well as pre-selection of patients (9) (10) (11) (12) (13) (14) . Pre-therapeutic estimation of the dose of lutetium-177 delivered to the target site, organs at risk, and the whole body would help to predict therapy response and side effects of a certain therapeutic activity and facilitate individual dose adjustment (15) . Currently pre-therapeutic dosimetry is performed using small amounts of [ 177 Lu]Lu-PSMA-617 as suitable alternatives using positron emission tomography (PET) nuclides are still to be established (13) . Due to the regulatory necessity of having to hospitalize the patient when using lutetium-177 for pre-therapeutic dosimetry it is often not performed at all. However, patients may benefit from higher therapeutic doses and therefore ways to implement individual dosimetry in the clinical workflow have to be investigated.
Currently gallium-68 is the most frequently used radionuclide for PET imaging utilized as [ 68 Ga]Ga-PSMA-11, which is currently the most commonly used PSMA-targeted PET tracer worldwide (8, 16) . Even though its decay characteristics are ideal for PET imaging and its good availability via 68 Ge/ 68 Ga generators, gallium-68 has disadvantages. Due to its high positron energy (β + = 89 %, Ē = 0.74 MeV) images tend to be more noisy compared to 18 F-labeled tracers. Moreover, its short physical half-life of 68 min limits its application as it only covers imaging periods of a few hours. Late imaging as well as extended dosimetric calculations simply cannot be performed using gallium-68. Another application gallium-68 is not suitable for is the use for intraoperative applications several hours post-injection (p.i.). For this reason, the positron-emitter scandium-44 as an alternative to gallium-68 is in the focus of current research (17) (18) (19) (20) resulting in initial human applications of [ 44 Sc]Sc-DOTATOC for imaging neuroendocrine tumors (21, 22) . First preclinical investigations with [ 44 Sc]Sc-PSMA-617 utilizing cyclotron-produced scandium-44 have been performed as well (23) . Scandium-44 (β + = 94 %, Ē = 0.597 MeV) has a physical half-life of 3.97 h and can be generated by a titanium-44 generator or produced by a cyclotron (22, 24) . Just like gallium-68, scandium-44 is a trivalent cation but its physical half-life is almost 4 times longer. It provides a longer imaging period covering up to 24 h post injection. Moreover, its coordination chemistry is similar to lutetium-177. Another potential advantage of Scandium(III) in nuclear medicine is the potential usage of its radioisotope scandium-47 (β − , primary γ-ray of 159 keV and t½ = 3.3 d) for therapy, constituting a matched pair of radioisotopes both for imaging and therapy thereby applicable in authentic Sc-labelled theranostic radiopharmaceuticals (20, (25) (26) (27) (28) (29) .
The growing interest in scandium-44 motivated research for production routes providing activities in the GBq range, which are not accessible via the generator. Scandium-44 production using the 180 MBq titanium-44 generator requires adequate quantities of the parent radionuclide titanium-44 which can be produced by the 45 Sc(p,2n) 44 Ti nuclear reaction. This production route limits the availability of titanium-44 because of the prolonged target irradiation times (30, 31) . In comparison cyclotron-production using the 44 Ca(p,n) 44 Sc nuclear reaction provides scandium-44 in sufficiently high activities with radionuclidic purities >99 % (32) and circumvents the problem of 44 Ti-waste management.
The aim of this work was to determine optimal conditions for radiolabeling of PSMA-617 with generator produced scandium-44 used as prostate cancer imaging agent. Investigation of parameters influencing reaction kinetics like incubation time, temperature and amount of precursor were performed. Stability of the labeled compound was examined in vitro. 
Materials and Methods
Reagents were purchased from Sigma-Aldrich (Germany) and used without further purification, unless otherwise stated. TraceSelect water was used for all generator and reaction solutions. No further special measures were taken regarding working under strict metal-free conditions. GMP-grade PSMA-617 was obtained from ABX advanced biochemical compounds (Radeberg, Germany).
Radioactivity was determined using an ionization chamber (ISOMED 2010; Nuklear-Medizintechnik Dresden GmbH, Germany). RadioTLC was performed using silica gel coated aluminum sheets (silica-gel 60 F254; Merck, Darmstadt, Germany) and glass microfiber chromatography paper impregnated with silica-gel (iTLC-SG, Agilent Technologies, Santa Clara, California). Analysis was performed with a single trace TLC scanner (PET-miniGita; Elysia-raytest, Straubenhardt, Germany). RadioHPLC was performed using an Agilent 1260 reverse phase HPLC system equipped with a Gabi γ-HPLC flow detector (Elysia-raytest, Straubenhardt, Germany) and a PC interface running Gina Star software (Elysia-raytest, Straubenhardt, Germany). Identification and quantification of long-living impurities was performed by a multi-channel analyzer for γ-spectroscopy (Mucha, Elysia-raytest, Straubenhardt, Germany). pH was measured using a pH-meter (SevenCompact 220, Mettler-Toledo, Columbus, USA).
Synthesis
Labelling of PSMA-617 with scandium-44 Scandium-44 was obtained from a prototype 185 MBq 44 Ti/ 44 Sc generator (26) . Scandium-44 was eluted and post-processed according to literature (20, 26, 28) . The resulting small volume (3 mL) of oxalate-free scandium-44 solution containing 142.4±12.7 MBq was used for further processing (20) .
For labeling of PSMA-617 with scandium-44, different volumes of PSMA-617 stock solution (1 mg/mL in water) were mixed with 3 mL of post-processed 44 Sc-eluate in 0.25 M ammonium acetate buffer (pH 4.0). The effect of PSMA-617 concentration on labeling yield was evaluated by use of different amounts of precursor varying from 14 to 26 nmol. Solutions were heated in a thermoblock (Thermomixer MHR 13; Hettich Benelux, Geldermalsen, Netherlands) for 20 min at 95 °C. The crude product was purified by solid-phase extraction utilizing C-18 cartridges (e.g. Sep-Pak C-18 Plus Short, Waters). The cartridges were preconditioned with 4 mL of ethanol and washed with 10 mL of water. The sample was subsequently loaded onto the cartridge providing retention of [ 44 Sc]Sc-PSMA-617. After washing the cartridge with 5 mL of water purified [ 44 Sc]Sc-PSMA-617 was eluted with 0.5 mL of pure ethanol.
Apparent molar activities were calculated on calibration time (end of synthesis). Determination of 44 Ti-content was determined at least 4 days, more than 20 half-lives of scandium-44, after the end of synthesis using a multi-channel analyzer for γ-spectroscopy. Titanium-44 breakthrough was calculated based on the 44 Sc activity at the end of synthesis.
In vitro evaluation
In vitro stability Stability was tested by addition of 20 µL (4.7±0.6 MBq) of purified [ 44 Sc]Sc-PSMA-617 to 500 µL of different solutions which were incubated for 24 h at 37° C and aliquots retrieved after t = 30 min, 1, 2, 4, 8 and 24 h. The investigated solutions are 0.9 % NaCl, human serum, aqueous solutions of different metal cations (Fe 3+ , Ca 2+ and Mg 2+ ) at concentration levels of 10 −2 M as well as chelators (DTPA, ETDA) with a final molar ratio of chelator to PSMA-617 equal to 100:1 as recommended in literature for 68 Ga-tracers (20, 33) .
Binding affinity and internalization
All cell studies were performed similar to literature (11) . Competitive binding and internalization was determined using the PSMA-positive (PSMA+) LNCaP cell line (European Collection of Cell Cultures, Salisbury, UK) derived from an androgen-sensitive human lymph node metastatic lesion of prostatic adenocarcinoma (ATCC CRL-1740). The cells were grown in RPMI 1640 medium (PAN-Biotech, Aidenbach, Germany) containing 10 % of fetal calf serum (FCS) and 1 % of L-glutamine. Cell cultures were kept in an atmosphere of 5 % CO2 at 37 °C in a humidified incubator.
A cell-based competitive assay with 68 Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC dimer ([ 68 Ga]Ga-PSMA-10 (16)) was used for the determination of binding affinity and expressed as K i values according to literature (11) . Twelve concentrations of nat Sc-PSMA-617 (0-5000 nM) were incubated for 45 min at 37°C with 0.75 nM (90 kBq) of [ 68 Ga]Ga-PSMA-10 together with PSMA+ LNCaP cells (10 5 LNCaP cells/well) followed by washing three times with ice-cold PBS. Radioactivity accumulated in the cells was measured using a gamma counter and the data fitted using a nonlinear regression algorithm (GraphPad Software) to calculate 50 % inhibitory concentrations (IC50 values).
Internalization was evaluated with PSMA+ LNCaP cells (10 5 LNCaP cells/well) seeded in poly-L-lysine coated plates 24 h before the experiment. The cells were incubated for 45 min at 37 °C with 32 nM of [ 44 Sc]Sc-PSMA-617 in 250 μL Opti-MEM medium. Additionally, for confirmation of specific cellular uptake, treatment of a second set of compounds with 500 μM/well of PSMA inhibitor 2-PMPA (2-(phosphonomethyl)pentane-1,5-dioic acid) was performed. Incubation was followed by washing with ice-cold PBS four times and twice with 50 mM glycine (pH 2.8) to remove surface-bound radioactivity. The internalized fraction was determined by lysis of the washed PSMA-positive LNCaP cells using 0.3 M NaOH. The radioactivity collected from the glycine and hydroxide fractions was measured in a gamma counter and calculated as %IA/10 6 LNCaP cells (%IA = percentage of added radioactivity).
First in-human study
[ 44 Sc]Sc-PSMA-617 for clinical application Labeling was performed with 40 µL (38 nmol) of PSMA-617 and 3 mL of post-processed scandium-44 in 0.25 M ammonium acetate and 160 µL of ethanol for 20 min at 95 °C. After C-18 purification with 1.5 mL 50 % of ethanol, the final product was formulated with 8.5 mL of 0.9 % NaCl and subsequent sterile filtration.
Quality control was performed according to the 25 MBq in a total volume of 10 mL. A Siemens Biograph 2 PET/CT (Siemens Medical Solutions, Erlangen, Germany) was used to acquire initial dynamic PET (30 min) of abdomen in list mode followed by static PET/CT (skull to mid-thigh) 45 min, 2 and 18 h post injection (p.i.). Reconstruction was performed using the iterative reconstruction algorithm implemented by the manufacturer including attenuation and scatter correction based on the low dose CT. For quantitative analysis, the dynamic list mode data were reconstructed as 6 images of 300 s.
Images at 120 min were compared visually to [ 68 Ga]Ga-PSMA-11 data sets of the same patients acquired 32 to 97 days before acquisition of the [ 44 Sc]Sc-PSMA-617 data. For evaluation of the signal-to-noise ratio in all [ 44 Sc]Sc-PSMA-617 data sets the mean activity concentration and the standard deviation was measured in fixed size regions in the liver (60 mm diameter), the lung (60 mm diameter) and a VOI outside the body (60 mm diameter). The ratio between standard deviation and mean uptake was used as measure for the noise ratio.
Mean standardized uptake values (SUV) were measured in fixed size volumes of interest (VOIs) in the kidneys (20 mm diameter), the liver (60 mm diameter), the parotic glands (15 mm Consequently for initial dosimetric evaluation VOIs were drawn around the source organs in the CT and transferred to all [ 44 Sc]Sc-PSMA-617 data sets for calculating average counts/mL over time. Total and % activity in source organs were determined and residence times were calculated accordingly using OLINDA/EXM software (Hermes, Germany). Organ absorbed doses and effective doses were calculated using OLINDA/EXM applying correction factor for patient weight. Results presented as mean organ absorbed dose and effective dose.
All data analysis was performed on MEDISO interview fusion software (MEDISO Medical Imaging Systems, Budapest, Hungary). MBq/nmol using cyclotron produced scandium-44 are described in literature (23) .
Results & Discussion

Synthesis
Solid phase extraction with C-18 cartridges (Sep-Pak C-18 Plus Short, Waters) showed to be a useful method to remove uncomplexed scandium-44 and acetate ions from the crude product solution. In a first step the cartridge was equilibrated with 5 mL of ethanol followed by 10 mL of water. Passing the reaction mixture through the cartridge allowed almost quantitative retention of [ 44 Sc]Sc-PSMA-617 with non-chelated scandium-44 being collected in the waste fraction. After a washing step with 10 mL of water the purified product was recovered in 0.5 mL of pure ethanol with > 90 % efficacy and used for further in vitro studies containing <0.9 % of uncomplexed scandium-44. Utilizing 21 nmol of the tracer resulted in an activity concentration of 233.93±27.33 MBq/mL in the purified fraction. In all quality control samples of the final product, no titanium-44 was detected.
For patient application, modifications of the radiolabeling procedure were performed in terms of precursor amount to ensure quantitative yields and additional ethanol content to prevent radiolysis in the initial reaction mixture. C-18 purification was included by default to remove potentially remaining uncomplexed scandium-44 as well as ammonium acetate buffer prior to reformulation in 0.9 % of NaCl. The apparent molar activity was 3.05±0. 36 Results for stability in physiological saline and human serum are similar to the ones presented above. After 24 h of incubation, more than 95 % of the labeled compound remained intact (Figure 4) .
The binding affinity of nat Sc-PSMA-617 to the target was determined indirectly by measuring its ability to compete with the dimeric PSMA inhibitor PSMA-10 labeled with gallium-68. The experimental setup was equivalent to those published for [ 177 Lu]Lu-PSMA-617 in order to allow direct comparison of data (11) . Various concentrations of nat Sc-PSMA-617 were allowed to compete with a fixed concentration of 0.75 nM of the 68 Ga-dimer for PSMA binding. Whilst the concentration of unlabeled ligand increased, the amount of radioligand bound to PSMA decreased. Nanomolar binding affinity of 4.7±0.8 nM was obtained for nat Sc-PSMA-617 with LNCaP cells. These results are in the same range as the values for binding affinities of nat Ga-and nat Lu-labelled versions of PSMA-617 (Table 3) .
[ 44 Sc]Sc-PSMA-617 was specifically internalized into human prostate carcinoma (LNCaP) cells up to 15.8±2.1 % IA/10 6 LNCaP cells (n = 4). The internalization value is within the limits of the standard deviation and directly comparable with the values for gallium-68 and lutetium-177 analogs (Table  3 , Figure 5 ). The results of all three radiotracers did not show any significant differences. (11) . Surface refers to the surface exposed fraction of the radioligand. Figure 7 . The differences found are in line with previous clinical studies (11) .
The tumor to liver ratios were in a range of 1. Using doses with little activity and scans performed at late time points of 19 h p.i., lesions were still detected using [ 44 Sc]Sc-PSMA-617 (Figure 8 ). Accumulated activity in the urinary tract or kidneys were no longer observed at this time point. Almost all remaining activity was accumulated in the metastatic tissue. Qualitative detection of PSMA-positive lesions was feasible as background activity was very low in the urinary tract and kidneys. Estimated residence times of the tracer in various organs are listed in Table  4 . For all organs the estimated residence times appear larger compared to the ones published in literature for [ 68 Ga]Ga-PSMA-617 (35) .
Based on this calculation an organ absorbed dose of 0.354 mSv/MBq of injected activity was obtained for the kidneys (range 0.180 -0.488 mSv/MBq) which is about twice the value of [ 68 Ga]Ga-PSMA-617 (0.206 mSv/MBq) as reported in literature (35) . The values for other organs are given in Table 5 . 
Conclusion
Radiolabeling of PSMA-617 with the generator-derived PET radionuclide scandium-44 and its eligibility as PET imaging agent for prostate cancer was investigated in detail. A manual synthesis procedure, guaranteeing safe preparation and reproducible quality of the final radiopharmaceutical as well as an adequate quality control protocol with respect to the guidelines of the European Pharmacopoeia was developed. During in vitro studies, the radiopharmaceutical presented high stability and showed similar binding and specific internalization in LNCaP cells compared to the 68 Gaand 177 Lu-labeled derivatives. Additional potential application of scandium-44 radiotracers, is image-guided radiosurgery using positron probes intraoperatively e.g. for detection of lymph node metastases. This procedure is feasible due to the longer half-life of scandium-44 compared to gallium-68. This concept has been well established (37) and it may benefit from higher resolution imaging using PET instead of SPECT tracers.
Potential drawbacks of scandium-44 as PET imaging agent may be the presence of additional high-energy gamma lines. However, in the visual comparison of gallium-68 and scandium-44 as well as the calculation of the signal to noise-ratio no significant differences were found. This observation may be caused by the reduced noise-level of scandium-44 due to the lower positron energy compared to gallium-68. In addition, optimization of PET acquisition parameters and noise reduction algorithms may be part of future work. Another general limitation of scandium-44 is the currently limited availability. As soon as clinical advantages of scandium-44 are shown and confirmed as part of future studies, availability of this promising nuclide will hopefully be granted.
The study presented as part of this publication confirms suitability of [ 44 Sc]Sc-PSMA-617 for PET imaging and pre-therapeutic dosimetry of prostate cancer. 
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